カテゴリ： 世界, 医療/バイオ, Market Monitor Global

軟部肉腫化学療法のグローバル市場展望 2023年-2029年：局所肉腫、転移性肉腫、その他肉腫

■ 英語タイトル：Chemotherapy for Soft Tissue Sarcomas Market, Global Outlook and Forecast 2023-2029

調査会社Market Monitor Global社が発行したリサーチレポート（データ管理コード：MMG23LY8407）■ 発行会社/調査会社：Market Monitor Global
■ 商品コード：MMG23LY8407
■ 発行日：2023年7月
■ 調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
■ 産業分野：医薬品＆ヘルスケア
■ ページ数：73
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Market Monitor Global社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[軟部肉腫化学療法のグローバル市場展望 2023年-2029年：局所肉腫、転移性肉腫、その他肉腫]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査レポートは次の情報を含め、世界の軟部肉腫化学療法市場規模と予測を収録しています。・世界の軟部肉腫化学療法市場：売上、2018年-2023年、2024年-2029年
・世界の軟部肉腫化学療法市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の軟部肉腫化学療法市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「局所肉腫」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

軟部肉腫化学療法のグローバル主要企業は、Roche、 Pfizer、 Johnson & Johnson、 GSK Plc、 Teva Pharmaceuticals、 Celgene、 Bristol Myers Squibb、 BeiGene、 Shenzhen Chipscreen、 Monopar Therapeutics、 Akeso Biopharmaなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、軟部肉腫化学療法のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の軟部肉腫化学療法市場：タイプ別、2018年-2023年、2024年-2029年
世界の軟部肉腫化学療法市場：タイプ別市場シェア、2022年
・局所肉腫、転移性肉腫、その他肉腫

世界の軟部肉腫化学療法市場：用途別、2018年-2023年、2024年-2029年
世界の軟部肉腫化学療法市場：用途別市場シェア、2022年
・病院、腫瘍センター、その他

世界の軟部肉腫化学療法市場：地域・国別、2018年-2023年、2024年-2029年
世界の軟部肉腫化学療法市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における軟部肉腫化学療法のグローバル売上、2018年-2023年
・主要企業における軟部肉腫化学療法のグローバル売上シェア、2022年
・主要企業における軟部肉腫化学療法のグローバル販売量、2018年-2023年
・主要企業における軟部肉腫化学療法のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Roche、 Pfizer、 Johnson & Johnson、 GSK Plc、 Teva Pharmaceuticals、 Celgene、 Bristol Myers Squibb、 BeiGene、 Shenzhen Chipscreen、 Monopar Therapeutics、 Akeso Biopharma

*************************************************************

・調査・分析レポートの概要
軟部肉腫化学療法市場の定義
市場セグメント
世界の軟部肉腫化学療法市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の軟部肉腫化学療法市場規模
世界の軟部肉腫化学療法市場規模：2022年 VS 2029年
世界の軟部肉腫化学療法市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの軟部肉腫化学療法の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の軟部肉腫化学療法製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：局所肉腫、転移性肉腫、その他肉腫
軟部肉腫化学療法のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院、腫瘍センター、その他
軟部肉腫化学療法の用途別グローバル売上・予測

・地域別市場分析
地域別軟部肉腫化学療法市場規模 2022年と2029年
地域別軟部肉腫化学療法売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Roche、 Pfizer、 Johnson & Johnson、 GSK Plc、 Teva Pharmaceuticals、 Celgene、 Bristol Myers Squibb、 BeiGene、 Shenzhen Chipscreen、 Monopar Therapeutics、 Akeso Biopharma
...

This report aims to provide a comprehensive presentation of the global market for Chemotherapy for Soft Tissue Sarcomas, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chemotherapy for Soft Tissue Sarcomas. This report contains market size and forecasts of Chemotherapy for Soft Tissue Sarcomas in global, including the following market information:
Global Chemotherapy for Soft Tissue Sarcomas Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Chemotherapy for Soft Tissue Sarcomas Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Chemotherapy for Soft Tissue Sarcomas companies in 2022 (%)
The global Chemotherapy for Soft Tissue Sarcomas market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Local Sarcoma Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Chemotherapy for Soft Tissue Sarcomas include Roche, Pfizer, Johnson & Johnson, GSK Plc, Teva Pharmaceuticals, Celgene, Bristol Myers Squibb, BeiGene and Shenzhen Chipscreen, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Chemotherapy for Soft Tissue Sarcomas manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Chemotherapy for Soft Tissue Sarcomas Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Chemotherapy for Soft Tissue Sarcomas Market Segment Percentages, by Type, 2022 (%)
Local Sarcoma
Metastatic Sarcoma
Other Sarcoma
Global Chemotherapy for Soft Tissue Sarcomas Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Chemotherapy for Soft Tissue Sarcomas Market Segment Percentages, by Application, 2022 (%)
Hospitals
Oncology Centers
Other
Global Chemotherapy for Soft Tissue Sarcomas Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Chemotherapy for Soft Tissue Sarcomas Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Chemotherapy for Soft Tissue Sarcomas revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Chemotherapy for Soft Tissue Sarcomas revenues share in global market, 2022 (%)
Key companies Chemotherapy for Soft Tissue Sarcomas sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Chemotherapy for Soft Tissue Sarcomas sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Roche
Pfizer
Johnson & Johnson
GSK Plc
Teva Pharmaceuticals
Celgene
Bristol Myers Squibb
BeiGene
Shenzhen Chipscreen
Monopar Therapeutics
Akeso Biopharma
Outline of Major Chapters:
Chapter 1: Introduces the definition of Chemotherapy for Soft Tissue Sarcomas, market overview.
Chapter 2: Global Chemotherapy for Soft Tissue Sarcomas market size in revenue and volume.
Chapter 3: Detailed analysis of Chemotherapy for Soft Tissue Sarcomas manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Chemotherapy for Soft Tissue Sarcomas in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Chemotherapy for Soft Tissue Sarcomas capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Introduction to Research & Analysis Reports
1.1 Chemotherapy for Soft Tissue Sarcomas Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Chemotherapy for Soft Tissue Sarcomas Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Chemotherapy for Soft Tissue Sarcomas Overall Market Size
2.1 Global Chemotherapy for Soft Tissue Sarcomas Market Size: 2022 VS 2029
2.2 Global Chemotherapy for Soft Tissue Sarcomas Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Chemotherapy for Soft Tissue Sarcomas Sales: 2018-2029
3 Company Landscape
3.1 Top Chemotherapy for Soft Tissue Sarcomas Players in Global Market
3.2 Top Global Chemotherapy for Soft Tissue Sarcomas Companies Ranked by Revenue
3.3 Global Chemotherapy for Soft Tissue Sarcomas Revenue by Companies
3.4 Global Chemotherapy for Soft Tissue Sarcomas Sales by Companies
3.5 Global Chemotherapy for Soft Tissue Sarcomas Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Chemotherapy for Soft Tissue Sarcomas Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Chemotherapy for Soft Tissue Sarcomas Product Type
3.8 Tier 1, Tier 2 and Tier 3 Chemotherapy for Soft Tissue Sarcomas Players in Global Market
3.8.1 List of Global Tier 1 Chemotherapy for Soft Tissue Sarcomas Companies
3.8.2 List of Global Tier 2 and Tier 3 Chemotherapy for Soft Tissue Sarcomas Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Chemotherapy for Soft Tissue Sarcomas Market Size Markets, 2022 & 2029
4.1.2 Local Sarcoma
4.1.3 Metastatic Sarcoma
4.1.4 Other Sarcoma
4.2 By Type – Global Chemotherapy for Soft Tissue Sarcomas Revenue & Forecasts
4.2.1 By Type – Global Chemotherapy for Soft Tissue Sarcomas Revenue, 2018-2023
4.2.2 By Type – Global Chemotherapy for Soft Tissue Sarcomas Revenue, 2024-2029
4.2.3 By Type – Global Chemotherapy for Soft Tissue Sarcomas Revenue Market Share, 2018-2029
4.3 By Type – Global Chemotherapy for Soft Tissue Sarcomas Sales & Forecasts
4.3.1 By Type – Global Chemotherapy for Soft Tissue Sarcomas Sales, 2018-2023
4.3.2 By Type – Global Chemotherapy for Soft Tissue Sarcomas Sales, 2024-2029
4.3.3 By Type – Global Chemotherapy for Soft Tissue Sarcomas Sales Market Share, 2018-2029
4.4 By Type – Global Chemotherapy for Soft Tissue Sarcomas Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Chemotherapy for Soft Tissue Sarcomas Market Size, 2022 & 2029
5.1.2 Hospitals
5.1.3 Oncology Centers
5.1.4 Other
5.2 By Application – Global Chemotherapy for Soft Tissue Sarcomas Revenue & Forecasts
5.2.1 By Application – Global Chemotherapy for Soft Tissue Sarcomas Revenue, 2018-2023
5.2.2 By Application – Global Chemotherapy for Soft Tissue Sarcomas Revenue, 2024-2029
5.2.3 By Application – Global Chemotherapy for Soft Tissue Sarcomas Revenue Market Share, 2018-2029
5.3 By Application – Global Chemotherapy for Soft Tissue Sarcomas Sales & Forecasts
5.3.1 By Application – Global Chemotherapy for Soft Tissue Sarcomas Sales, 2018-2023
5.3.2 By Application – Global Chemotherapy for Soft Tissue Sarcomas Sales, 2024-2029
5.3.3 By Application – Global Chemotherapy for Soft Tissue Sarcomas Sales Market Share, 2018-2029
5.4 By Application – Global Chemotherapy for Soft Tissue Sarcomas Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Chemotherapy for Soft Tissue Sarcomas Market Size, 2022 & 2029
6.2 By Region – Global Chemotherapy for Soft Tissue Sarcomas Revenue & Forecasts
6.2.1 By Region – Global Chemotherapy for Soft Tissue Sarcomas Revenue, 2018-2023
6.2.2 By Region – Global Chemotherapy for Soft Tissue Sarcomas Revenue, 2024-2029
6.2.3 By Region – Global Chemotherapy for Soft Tissue Sarcomas Revenue Market Share, 2018-2029
6.3 By Region – Global Chemotherapy for Soft Tissue Sarcomas Sales & Forecasts
6.3.1 By Region – Global Chemotherapy for Soft Tissue Sarcomas Sales, 2018-2023
6.3.2 By Region – Global Chemotherapy for Soft Tissue Sarcomas Sales, 2024-2029
6.3.3 By Region – Global Chemotherapy for Soft Tissue Sarcomas Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Chemotherapy for Soft Tissue Sarcomas Revenue, 2018-2029
6.4.2 By Country – North America Chemotherapy for Soft Tissue Sarcomas Sales, 2018-2029
6.4.3 US Chemotherapy for Soft Tissue Sarcomas Market Size, 2018-2029
6.4.4 Canada Chemotherapy for Soft Tissue Sarcomas Market Size, 2018-2029
6.4.5 Mexico Chemotherapy for Soft Tissue Sarcomas Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Chemotherapy for Soft Tissue Sarcomas Revenue, 2018-2029
6.5.2 By Country – Europe Chemotherapy for Soft Tissue Sarcomas Sales, 2018-2029
6.5.3 Germany Chemotherapy for Soft Tissue Sarcomas Market Size, 2018-2029
6.5.4 France Chemotherapy for Soft Tissue Sarcomas Market Size, 2018-2029
6.5.5 U.K. Chemotherapy for Soft Tissue Sarcomas Market Size, 2018-2029
6.5.6 Italy Chemotherapy for Soft Tissue Sarcomas Market Size, 2018-2029
6.5.7 Russia Chemotherapy for Soft Tissue Sarcomas Market Size, 2018-2029
6.5.8 Nordic Countries Chemotherapy for Soft Tissue Sarcomas Market Size, 2018-2029
6.5.9 Benelux Chemotherapy for Soft Tissue Sarcomas Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Chemotherapy for Soft Tissue Sarcomas Revenue, 2018-2029
6.6.2 By Region – Asia Chemotherapy for Soft Tissue Sarcomas Sales, 2018-2029
6.6.3 China Chemotherapy for Soft Tissue Sarcomas Market Size, 2018-2029
6.6.4 Japan Chemotherapy for Soft Tissue Sarcomas Market Size, 2018-2029
6.6.5 South Korea Chemotherapy for Soft Tissue Sarcomas Market Size, 2018-2029
6.6.6 Southeast Asia Chemotherapy for Soft Tissue Sarcomas Market Size, 2018-2029
6.6.7 India Chemotherapy for Soft Tissue Sarcomas Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Chemotherapy for Soft Tissue Sarcomas Revenue, 2018-2029
6.7.2 By Country – South America Chemotherapy for Soft Tissue Sarcomas Sales, 2018-2029
6.7.3 Brazil Chemotherapy for Soft Tissue Sarcomas Market Size, 2018-2029
6.7.4 Argentina Chemotherapy for Soft Tissue Sarcomas Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Chemotherapy for Soft Tissue Sarcomas Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Chemotherapy for Soft Tissue Sarcomas Sales, 2018-2029
6.8.3 Turkey Chemotherapy for Soft Tissue Sarcomas Market Size, 2018-2029
6.8.4 Israel Chemotherapy for Soft Tissue Sarcomas Market Size, 2018-2029
6.8.5 Saudi Arabia Chemotherapy for Soft Tissue Sarcomas Market Size, 2018-2029
6.8.6 UAE Chemotherapy for Soft Tissue Sarcomas Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Roche
7.1.1 Roche Company Summary
7.1.2 Roche Business Overview
7.1.3 Roche Chemotherapy for Soft Tissue Sarcomas Major Product Offerings
7.1.4 Roche Chemotherapy for Soft Tissue Sarcomas Sales and Revenue in Global (2018-2023)
7.1.5 Roche Key News & Latest Developments
7.2 Pfizer
7.2.1 Pfizer Company Summary
7.2.2 Pfizer Business Overview
7.2.3 Pfizer Chemotherapy for Soft Tissue Sarcomas Major Product Offerings
7.2.4 Pfizer Chemotherapy for Soft Tissue Sarcomas Sales and Revenue in Global (2018-2023)
7.2.5 Pfizer Key News & Latest Developments
7.3 Johnson & Johnson
7.3.1 Johnson & Johnson Company Summary
7.3.2 Johnson & Johnson Business Overview
7.3.3 Johnson & Johnson Chemotherapy for Soft Tissue Sarcomas Major Product Offerings
7.3.4 Johnson & Johnson Chemotherapy for Soft Tissue Sarcomas Sales and Revenue in Global (2018-2023)
7.3.5 Johnson & Johnson Key News & Latest Developments
7.4 GSK Plc
7.4.1 GSK Plc Company Summary
7.4.2 GSK Plc Business Overview
7.4.3 GSK Plc Chemotherapy for Soft Tissue Sarcomas Major Product Offerings
7.4.4 GSK Plc Chemotherapy for Soft Tissue Sarcomas Sales and Revenue in Global (2018-2023)
7.4.5 GSK Plc Key News & Latest Developments
7.5 Teva Pharmaceuticals
7.5.1 Teva Pharmaceuticals Company Summary
7.5.2 Teva Pharmaceuticals Business Overview
7.5.3 Teva Pharmaceuticals Chemotherapy for Soft Tissue Sarcomas Major Product Offerings
7.5.4 Teva Pharmaceuticals Chemotherapy for Soft Tissue Sarcomas Sales and Revenue in Global (2018-2023)
7.5.5 Teva Pharmaceuticals Key News & Latest Developments
7.6 Celgene
7.6.1 Celgene Company Summary
7.6.2 Celgene Business Overview
7.6.3 Celgene Chemotherapy for Soft Tissue Sarcomas Major Product Offerings
7.6.4 Celgene Chemotherapy for Soft Tissue Sarcomas Sales and Revenue in Global (2018-2023)
7.6.5 Celgene Key News & Latest Developments
7.7 Bristol Myers Squibb
7.7.1 Bristol Myers Squibb Company Summary
7.7.2 Bristol Myers Squibb Business Overview
7.7.3 Bristol Myers Squibb Chemotherapy for Soft Tissue Sarcomas Major Product Offerings
7.7.4 Bristol Myers Squibb Chemotherapy for Soft Tissue Sarcomas Sales and Revenue in Global (2018-2023)
7.7.5 Bristol Myers Squibb Key News & Latest Developments
7.8 BeiGene
7.8.1 BeiGene Company Summary
7.8.2 BeiGene Business Overview
7.8.3 BeiGene Chemotherapy for Soft Tissue Sarcomas Major Product Offerings
7.8.4 BeiGene Chemotherapy for Soft Tissue Sarcomas Sales and Revenue in Global (2018-2023)
7.8.5 BeiGene Key News & Latest Developments
7.9 Shenzhen Chipscreen
7.9.1 Shenzhen Chipscreen Company Summary
7.9.2 Shenzhen Chipscreen Business Overview
7.9.3 Shenzhen Chipscreen Chemotherapy for Soft Tissue Sarcomas Major Product Offerings
7.9.4 Shenzhen Chipscreen Chemotherapy for Soft Tissue Sarcomas Sales and Revenue in Global (2018-2023)
7.9.5 Shenzhen Chipscreen Key News & Latest Developments
7.10 Monopar Therapeutics
7.10.1 Monopar Therapeutics Company Summary
7.10.2 Monopar Therapeutics Business Overview
7.10.3 Monopar Therapeutics Chemotherapy for Soft Tissue Sarcomas Major Product Offerings
7.10.4 Monopar Therapeutics Chemotherapy for Soft Tissue Sarcomas Sales and Revenue in Global (2018-2023)
7.10.5 Monopar Therapeutics Key News & Latest Developments
7.11 Akeso Biopharma
7.11.1 Akeso Biopharma Company Summary
7.11.2 Akeso Biopharma Chemotherapy for Soft Tissue Sarcomas Business Overview
7.11.3 Akeso Biopharma Chemotherapy for Soft Tissue Sarcomas Major Product Offerings
7.11.4 Akeso Biopharma Chemotherapy for Soft Tissue Sarcomas Sales and Revenue in Global (2018-2023)
7.11.5 Akeso Biopharma Key News & Latest Developments
8 Global Chemotherapy for Soft Tissue Sarcomas Production Capacity, Analysis
8.1 Global Chemotherapy for Soft Tissue Sarcomas Production Capacity, 2018-2029
8.2 Chemotherapy for Soft Tissue Sarcomas Production Capacity of Key Manufacturers in Global Market
8.3 Global Chemotherapy for Soft Tissue Sarcomas Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Chemotherapy for Soft Tissue Sarcomas Supply Chain Analysis
10.1 Chemotherapy for Soft Tissue Sarcomas Industry Value Chain
10.2 Chemotherapy for Soft Tissue Sarcomas Upstream Market
10.3 Chemotherapy for Soft Tissue Sarcomas Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Chemotherapy for Soft Tissue Sarcomas Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 軟組織超音波手術器具のグローバル市場展望 2023年-2029年：切断型、固化型、縫合型
  • 高体温化学療法装置のグローバル市場展望 2023年-2029年：高精度温度制御、低精度温度制御
  • 組織工学骨のグローバル市場展望 2023年-2029年：無機材料、有機材料、複合材料
  • 使い捨て組織閉鎖クリップのグローバル市場展望 2023年-2029年：大クリップ、中クリップ、小クリップ
  • 羊膜組織移植片のグローバル市場展望 2023年-2029年：単層羊膜組織移植片、二層羊膜組織移植片
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(MMG23LY8407 )"軟部肉腫化学療法のグローバル市場展望 2023年-2029年：局所肉腫、転移性肉腫、その他肉腫" (英文：Chemotherapy for Soft Tissue Sarcomas Market, Global Outlook and Forecast 2023-2029)はMarket Monitor Global社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。